Drug Profile


Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; PTK-0796; PTK796

Latest Information Update: 13 Apr 2017

Price : $50

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Merck & Co; Paratek Pharmaceuticals
  • Class Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia; Skin and soft tissue infections
  • Phase I Nosocomial infections; Urinary tract infections
  • Preclinical Acute sinusitis
  • Research Anthrax; Plague

Most Recent Events

  • 18 Apr 2017 Paratek plans a proof-of-concept phase II trial of omadacycline in Complicated urinary tract infections in December 2017
  • 03 Apr 2017 Topline efficacy and adverse events data from the phase III OPTIC trial in Community-acquired bacterial pneumonia released by Paratek Pharmaceuticals
  • 18 Jan 2017 Paratek completes enrolment in a Phase-III clinical trials for Community-acquired pneumonia in USA, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Latvia, Slovakia, Spain, Belgium, Israel, South Korea, South Africa, Taiwan, Ukraine and Poland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top